A cyclohexa-1,3,5-triene-1,3,5-triol CEP of the European Pharmacopoeia monograph is often referred to as a cyclohexa-1,3,5-triene-1,3,5-triol Certificate of Suitability (COS). The purpose of a cyclohexa-1,3,5-triene-1,3,5-triol CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of cyclohexa-1,3,5-triene-1,3,5-triol EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of cyclohexa-1,3,5-triene-1,3,5-triol to their clients by showing that a cyclohexa-1,3,5-triene-1,3,5-triol CEP has been issued for it. The manufacturer submits a cyclohexa-1,3,5-triene-1,3,5-triol CEP (COS) as part of the market authorization procedure, and it takes on the role of a cyclohexa-1,3,5-triene-1,3,5-triol CEP holder for the record. Additionally, the data presented in the cyclohexa-1,3,5-triene-1,3,5-triol CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the cyclohexa-1,3,5-triene-1,3,5-triol DMF.
A cyclohexa-1,3,5-triene-1,3,5-triol CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. cyclohexa-1,3,5-triene-1,3,5-triol CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of cyclohexa-1,3,5-triene-1,3,5-triol suppliers with CEP (COS) on PharmaCompass.